text_1: Combining phosphatidylinositide 3-kinase and MEK 1/2 inhibitors is effective at treating KRAS mutant tumors.
text_2: In contrast, mouse lung cancers driven by mutant Kras did not substantially respond to single-agent NVP-BEZ235.